Biology is ready.
Delivery is not.
A clinic-led biologic delivery system built on controlled microtip technology.
ExoGenis combines a single-use dissolvable microtip patch, a first exosome-associated formulation, and a professional-use protocol to support controlled upper-skin placement beyond passive topical absorption, without injections.
First MVP: aesthetic recovery + between-treatment maintenance.
- Skin delivery infrastructure
A new category of controlled skin delivery
ExoGenis is building a biologic-compatible microtip delivery platform designed to sit between passive topical products and procedure-heavy delivery routes. The system is being developed for controlled, repeatable, protocol-based upper-skin delivery in professional aesthetic and dermatology workflows.
.svg)
Removable Patch
Clinic-friendly backing designed for clean application, handling, and removal.
Dissolvable Microtips
Short dissolvable microtips designed to create temporary microchannels and release active formulations into the upper skin layers.
.svg)
Protocol-Based Use
Single-use consumable format designed for professional workflows, post-procedure recovery, and clinic-guided maintenance.
- PATCH ARCHITECTURE
Controlled upper skin delivery
ExoGenis separates the patch into two functional layers: a removable backing for placement and handling, and an active microtip layer designed to dissolve or release regenerative payload into the skin.
ExoGenis is designed as a two-layer delivery system: a removable backing for clean placement and handling, and a dissolvable microtip layer designed to create temporary microchannels and release active formulations into the upper skin layers.
This architecture is being developed to support defined dosing, clean application, and repeatable use across professional protocols
- Clinic Workflow
Designed to fit professional skin
workflows
ExoGenis is designed as a clinic-friendly delivery step that can be added after selected aesthetic procedures or used between visits as part of a clinic-guided maintenance protocol, without requiring new capital equipment.
This architecture is being developed to support defined dosing, clean application and repeatable use across clinical protocols.
Professional treatment
Used after selected procedures such as laser, RF, microneedling, peels, or other clinic-led skin treatments.
EXOGENIS Patch application
A removable patch with dissolvable microtips is applied as a controlled delivery step.
Clinic-GUIDED continuation
Protocols can extend beyond the treatment room through repeatable, clinic-guided use between visits.
Follow-up
Supports structured follow-up, adherence tracking, and future treatment planning.
The missing layer between treatments
Bridging the gap between surface-level topicals and invasive injectables.
TOPICALS
Penetration-limited
Conventional topicals largely remain near the surface and can show variable absorption.
MICROINFUSION
Variable / manual
Manual or device-assisted delivery can vary by technique, depth, pressure, and distribution.
EXOGENIS Delivery system
Controlled / repeatable
Designed to deliver defined formulation amounts through a controlled dissolvable microtip array
INJECTIONS
Invasive / deeper
Can bypass the skin barrier, but adds invasiveness, complexity, and injector dependency.
- Why Clinics May Add ExoGenis
Adding controlled delivery without new equipment.
.svg)
Structured protocol feedback
Capture clinic and patient feedback during pilot use to support protocol refinement and future validation.
Clinic-guided continuity
Supports structured between-treatment care, repeat protocols, and stronger patient connection to the clinic.
Partner-led validation
Built for selected clinic and industry partners who want to participate in early workflow, usability, and protocol validation.
Apply for Pilot Access
We are strictly working with professional and validation partners during this technical validation phase. Apply to register interest for your clinic.
A clinic-controlled delivery layer between procedures.
Designed for controlled use
.svg)
Payload Compatibility
- Designed for fragile active formulations.
- Microtip/coating architecture under development.
- MVP: exosome-associated formulation first.
.svg)
Safety-Oriented Design
- Single-use format.
- No retained solid needles.
- Designed for controlled upper-skin interaction.
.svg)
Validation Pathway
- Ex vivo skin interaction studies completed.
- Ex vivo skin interaction studies completed.
- Human tolerability and workflow validation planned.
Built with technical
and clinical validation partners
ExoGenis is being developed with scientific, technical and commercialization partners across microneedle engineering, coating validation, skin model testing and early market validation.
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
- Ambition
Building the missing delivery layer between topicals and injections
Our ambition is to build Denmark's first dermatology-focused biologic delivery platform: A controlled delivery layer between topical skincare and injectable procedures.
ExoGenis starts with regenerative dermatology and clinic-integrated skin protocols, with longer-term potential across broader biologic delivery applications in skin.
Interested in piloting ExoGenis?
We are looking for strategic partners in the professional skin care and dermatology space to join our exclusive pilot program.
Professional and partner access only during validation phase.
Stay informed about our technology and future availability. Talk to us